These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 17484896)

  • 81. Now Is the Time to Quickly Eliminate Barriers Along the Hepatitis C Cascade of Care.
    Cooper CL
    J Infect Dis; 2018 May; 217(12):1858-1860. PubMed ID: 29534217
    [No Abstract]   [Full Text] [Related]  

  • 82. Lethal mutagenesis of an RNA plant virus via lethal defection.
    Díaz-Martínez L; Brichette-Mieg I; Pineño-Ramos A; Domínguez-Huerta G; Grande-Pérez A
    Sci Rep; 2018 Jan; 8(1):1444. PubMed ID: 29362502
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Favipiravir elicits antiviral mutagenesis during virus replication in vivo.
    Arias A; Thorne L; Goodfellow I
    Elife; 2014 Oct; 3():e03679. PubMed ID: 25333492
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Extinction of hepatitis C virus by ribavirin in hepatoma cells involves lethal mutagenesis.
    Ortega-Prieto AM; Sheldon J; Grande-Pérez A; Tejero H; Gregori J; Quer J; Esteban JI; Domingo E; Perales C
    PLoS One; 2013; 8(8):e71039. PubMed ID: 23976977
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Ribavirin can be mutagenic for arenaviruses.
    Moreno H; Gallego I; Sevilla N; de la Torre JC; Domingo E; Martín V
    J Virol; 2011 Jul; 85(14):7246-55. PubMed ID: 21561907
    [TBL] [Abstract][Full Text] [Related]  

  • 86. A multi-step process of viral adaptation to a mutagenic nucleoside analogue by modulation of transition types leads to extinction-escape.
    Agudo R; Ferrer-Orta C; Arias A; de la Higuera I; Perales C; Pérez-Luque R; Verdaguer N; Domingo E
    PLoS Pathog; 2010 Aug; 6(8):e1001072. PubMed ID: 20865120
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Structure of foot-and-mouth disease virus mutant polymerases with reduced sensitivity to ribavirin.
    Ferrer-Orta C; Sierra M; Agudo R; de la Higuera I; Arias A; Pérez-Luque R; Escarmís C; Domingo E; Verdaguer N
    J Virol; 2010 Jun; 84(12):6188-99. PubMed ID: 20392853
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Treatment of hepatitis C virus infection with interferon and small molecule direct antivirals: viral kinetics and modeling.
    Rong L; Perelson AS
    Crit Rev Immunol; 2010; 30(2):131-48. PubMed ID: 20370626
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Potential benefits of sequential inhibitor-mutagen treatments of RNA virus infections.
    Perales C; Agudo R; Tejero H; Manrubia SC; Domingo E
    PLoS Pathog; 2009 Nov; 5(11):e1000658. PubMed ID: 19911056
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Therapeutically targeting RNA viruses via lethal mutagenesis.
    Graci JD; Cameron CE
    Future Virol; 2008 Nov; 3(6):553-566. PubMed ID: 19727424
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Counteracting quasispecies adaptability: extinction of a ribavirin-resistant virus mutant by an alternative mutagenic treatment.
    Perales C; Agudo R; Domingo E
    PLoS One; 2009; 4(5):e5554. PubMed ID: 19436746
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Evidence for action of ribavirin through the hepatitis C virus RNA polymerase.
    Cannon NA; Donlin MJ; Mayes LM; Lyra AC; Di Bisceglie AM; Tavis JE
    J Viral Hepat; 2009 Aug; 16(8):595-604. PubMed ID: 19243495
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Mathematical modeling of HCV infection and treatment.
    Dahari H; Shudo E; Ribeiro RM; Perelson AS
    Methods Mol Biol; 2009; 510():439-53. PubMed ID: 19009281
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Virology of hepatitis B and C viruses and antiviral targets.
    Pawlotsky JM
    J Hepatol; 2006; 44(1 Suppl):S10-3. PubMed ID: 16338022
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Ribavirin: is it a mutagen for hepatitis C virus?
    Perelson AS; Layden TJ
    Gastroenterology; 2007 May; 132(5):2050-2. PubMed ID: 17484896
    [No Abstract]   [Full Text] [Related]  

  • 96. Analysis of sequence configurations of the PKR-interacting HCV proteins from plasma and PBMC as predictors of response to interferon-alpha and ribavirin therapy in HIV-coinfected patients.
    Bolcic F; Bull L; Martinez L; Reynoso R; Salomon H; Arduino R; Barnett B; Quarleri J
    Intervirology; 2008; 51(4):261-4. PubMed ID: 18824873
    [No Abstract]   [Full Text] [Related]  

  • 97. A mutational shift from domain III to II in the internal ribosome entry site of hepatitis C virus after interferon-ribavirin therapy.
    Ogata K; Kashiwagi T; Iwahashi J; Hara K; Honda H; Ide T; Kumashiro R; Kohara M; Sata M; Watanabe H; Hamada N
    Arch Virol; 2008; 153(8):1575-9. PubMed ID: 18592133
    [TBL] [Abstract][Full Text] [Related]  

  • 98.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 99.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 100.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.